ACRO Biomedical Q2 net loss widens to $21,356; operating expenses rise to $17,554
Reuters2026/08/14 10:06- ACRO Biomedical posted a net loss of $21,356 for the quarter ended June 30, 2026, widening from $15,562.
- Operating expenses climbed to $17,554 from $13,614, mainly on general and administrative costs and public-company professional fees.
- Interest expense to two minority stockholders rose to $3,802 from $1,948; the company reported no revenue.
- Cash was $3,648 at June 30, 2026, while working capital deficit widened to $444,789 from $386,964 at Dec. 31, 2025.
- Management said it had no sales since Dec. 31, 2022, and continues to rely on minority-stockholder advances for funding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
